What would it cost to license or adopt this technology?+
The project was funded with EUR 6,733,580 in EU contribution across 12 partners. Licensing terms would need to be negotiated with the coordinator (CSIC, Spain) and the 5 SME partners who hold commercial rights. Based on available project data, specific licensing fees are not published.
Can this work at industrial production scale?+
The project used Bacillus subtilis and Escherichia coli — two of the most widely used industrial production organisms with well-established scale-up protocols. The technology optimizes existing fermentation processes rather than replacing them, which lowers the scale-up barrier. However, the deliverables describe chassis characterization and data analysis, suggesting scale-up validation may still be needed.
Who owns the intellectual property?+
IP is shared among the 12-partner consortium across 9 countries (AT, CH, CZ, DE, DK, ES, FR, IT, NL). The 5 SME partners were specifically tasked with translating the technology into market applications. Contact the coordinator CSIC or SciTransfer for IP access details.
Which production processes does this actually improve?+
The project targeted three specific industrial sectors: pharmaceutical ingredient production, cosmetics active production, and animal feed ingredient production. Each sector had dedicated microbial chassis lines developed and characterized with full omics data (transcriptomics, proteomics, metabolomics).
How long before this could be integrated into our production line?+
The project ran from 2017 to 2021 and produced 23 deliverables including second-generation microbial chassis for cosmetics and feed. Integration timeline would depend on your specific production organism and process, but the technology is designed to work with standard industrial bacteria. Based on available project data, pilot-scale manufacturing validation would be the next step.
Is this compliant with EU regulations for biotech production?+
The project was funded under Horizon 2020 topic BIOTEC-03-2016 and includes a formal Data Management Plan. Regulatory compliance for specific products (pharma, cosmetics, feed) would depend on the end application and would need to be addressed during commercialization.
What technical support is available?+
The consortium includes 5 universities, 2 research organizations, and 5 industry partners with expertise spanning synthetic biology, systems biology, and mathematical modeling. The project produced detailed transcriptomics, proteomics, and metabolomics analyses that could support technology transfer.
